This article needs additional citations for verification. (July 2020)
This article relies largely or entirely on a single source. (July 2022)
Corixa was a biotechnology/pharmaceutical company based in Seattle, Washington, involved in the development of immunotherapeutics to combat autoimmune diseases, infectious diseases, and cancer. It was founded in 1994. It operated a laboratory and production facility in Hamilton, Montana.
|Founded||1994 in Seattle, Washington|
|Defunct||March 31, 2006|
|Successor||acquired by GlaxoSmithKline|
Number of locations
|Parent||GlaxoSmithKline (United States)|
On 12 July 2005, the European pharmaceuticals giant GlaxoSmithKline completed the acquisition of Corixa. GSK had formerly made use of the Corixa's MPL (Monophosphoryl lipid A, a derivative of the lipid A molecule), an adjuvant in some of their vaccines.
On 31 March 2006, Corixa's doors closed after over 11 years in business.
- "Glaxo to acquire Corixa for $300 million". Market Watch. April 29, 2005.